Immunomax lyophilisate for injection 200ed bottle №3

Active ingredient

Lyophilized powder for solution for i / m administration:
1 vial contains an acidic peptidoglycan with a molecular weight of 1000-40000 kDa 100 U or 200 U;
in a bottle complete with a solvent (water d / and 2 ml - amp.), a syringe and a napkin; in a pack of cardboard 3 bottle.

Pharmacology

Immunomodulator Immunomax enhances immune defense against viral and bacterial infections. Immunophar-makologicheskie mechanisms of action of the drug is that Immunomax activates the following parts of the immune system:

• NK cells that, 2-3 hours after exposure to Immunomax, strongly express CD69 activation molecules. The cytolytic activity of NK cells increases by 3 times;
• circulating monocytes after 2-4 hours after activation Immunomax begin to secrete cytokines: interleukin-8, interleukin-1beta and tumor necrosis factor alpha;
• neutrophilic granulocytes are activated by monocytes, the drug has no direct effect on neutrophilic granulocytes. Interleukin-8 secreted by monocytes causes activation of neutrophilic granulocytes, which clearly manifests itself 24 hours after exposure to Immunomax;
• tissue macrophages, which is manifested in changes in the morphology of these cells, increased production of bactericidal substances, changes in the activity of 5'-nucleotidase;
• the formation of antibodies against foreign antigens, soluble and particulate;

Immunomax enhances protection against infections caused by viruses (human papillomavirus, herpes simplex virus, parvovirus, plague virus carnivorous, etc.) or bacteria (E. coli, salmonella, staphylococcus, chlamydia, mycoplasma, ureaplasma, etc.). This effect of the drug is manifested in adults and newborns with the introduction of Immunomax in various ways: intramuscularly, intravenously, intraperitoneally, per os.

Indications and usage

For the correction of weakened immunity;
For the treatment of pathological conditions (warts, warts, dysplasia, etc.) caused by human papillomavirus;
For the treatment of infections caused by herpes simplex virus, chlamydia, mycoplasma, ureaplasma, other bacteria and viruses.

Contraindications

Hypersensitivity to Immunomax; children under 12 years old.

Dosage and administration

Recommended dose for adults and children 12 years and older is 100-200 IU intramuscularly, once a day. Before use, the contents of the vial (ampoule) are dissolved in 1 ml of water for injection, injected intramuscularly at 100-200 U, depending on the severity of the disease.
The course of treatment - 6 injections in 1, 2, 3, 8, 9, 10 days of treatment.
For the treatment of recurrent anogenital warts A course of 6 injections of 200 U of Immunomax is combined with warts destruction using one of the generally accepted methods: cryodestruction, electrocoagulation, laser destruction, or Solcoderm.
DTo treat infections caused by bacteria or viruses conduct a course of 6 injections of 100-200 IU Immunomax.
For the correction of weakened immunity conduct a course of 3-6 injections of 100-200 IU Immunomax.

No data are available on the effects of Immunomax on pregnant women. As with other drugs, Immunomax should not be used during pregnancy unless the benefits to the patient do not exceed the possible risk to the fetus. Immunomax is not recommended for nursing mothers.

Storage conditions

Store at temperatures from +4 to + 8 ° C.